KFS
REGN icon

Keynote Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Keynote Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Buy
1,339
+201
+18% +$137K 0.39% 70
2026
Q1 		$879K Buy
1,138
+2
+0.2% +$1.53K 0.47% 61
2025
Q4 		$877K Buy
1,136
+43
+4% +$29.2K 0.49% 58
2025
Q3 		$615K Buy
1,093
+221
+25% +$125K 0.37% 76
2025
Q2 		$458K Buy
872
+245
+39% +$137K 0.31% 88
2025
Q1 		$398K Buy
627
+88
+16% +$60.5K 0.28% 97
2024
Q4 		$384K Buy
539
+41
+8% +$34.4K 0.29% 97
2024
Q3 		$524K Sell
498
-18
-3% -$20K 0.4% 72
2024
Q2 		$542K Buy
516
+16
+3% +$15.5K 0.45% 62
2024
Q1 		$481K Buy
+500
New +$475K 0.4% 72

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Keynote Financial Services's REGN Position: Q2 2026 in Review

Keynote Financial Services increased its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, buying an estimated $137K and bringing the position to 1,339 shares worth $835K. The position accounts for 0.39% of the portfolio, ranked #70.

Keynote Financial Services first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $879K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Keynote Financial Services held 1,339 shares of Regeneron Pharmaceuticals worth $835K as of Q2 2026.
  • Keynote Financial Services bought 201 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $137K.
  • Regeneron Pharmaceuticals made up 0.39% of Keynote Financial Services's portfolio in Q2 2026, its #70 holding.
  • Keynote Financial Services first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Keynote Financial Services's Regeneron Pharmaceuticals position peaked at $879K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Keynote Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.